Premium
Time course of changes in striatal dopamine transporters and D 2 receptors with specific iodinated markers in a rat model of Parkinson's disease
Author(s) -
Chalon Sylvie,
Emond Patrick,
Bodard Sylvie,
Vilar MariePaule,
Thiercelin Cynthia,
Besnard, JeanClaude,
Guilloteau Denis
Publication year - 1999
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/(sici)1098-2396(199902)31:2<134::aid-syn6>3.0.co;2-v
Subject(s) - dopamine transporter , striatum , dopamine receptor d2 , dopamine , postsynaptic potential , chemistry , ligand (biochemistry) , receptor , dopamine receptor , transporter , medicine , pharmacology , endocrinology , neuroscience , psychology , dopaminergic , biochemistry , gene
The time course of the loss in presynaptic dopamine transporters (DAT) and of the increase in postsynaptic dopamine D 2 receptors (D 2 R) was studied in a rat model of Parkinson's disease. For this, in vitro autoradiographic experiments were performed in the striatum using (E)‐N‐(3‐iodoprop‐2‐enyl)‐2β‐carbomethoxy‐3β‐(4′‐methylphenyl) nortropane (PE2I), a new single photon emission tomography (SPET) ligand for DAT, and iodobenzamide (IBZM), a SPET ligand for D 2 R. A significant decrease in [ 125 I]PE2I binding was observed as early as 24 h after 6‐hydroxydopamine lesion, whereas no change occurred in [ 125 I]IBZM binding. At 48 h postlesion, PE2I binding was 50% decreased, while IBZM binding was 30% increased. Between 3 and 14 days postlesion, PE2I binding had almost totally disappeared and IBZM binding remained increased by around 40–50%. From these animal experiments, it can be assumed that PE2I would be very efficient for the detection of a reduction in the number of DAT reflecting neuronal loss, thus allowing early diagnosis of Parkinson's disease. The exploration of both DAT and D 2 R would improve follow‐up of this disease. Synapse 31:134–139, 1999. © 1999 Wiley‐Liss, Inc.